ARTHROPLASTY
AAOS: Thrombin-based hemostatic reduces blood loss, but not haemoglobin loss, in TKA
108 patients undergoing primary unilateral total knee arthroplasty (TKA) were randomized to receive either a thrombin-based topical hemostatic matrix sealant with electrocautery or electrocautery alone. The purpose of this study was to determine whether this hemostatic agent is effective for reducing blood loss and transfusion rates. Results indicated that the use of the hemostatic agent was associated with a significantly lower mean drain output and calculated blood loss, however mean haemoglobin loss and the number of patients requiring a blood transfusion were similar between the treatment and control groups. Based on these findings, the clinical importance of this treatment is called into question.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
